导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.83% | 1715/4773 |
| 近一周 | 1.08% | 120/5458 |
| 近一月 | 4.69% | 128/5421 |
| 近一季 | 2.96% | 441/5205 |
| 近半年 | 0.23% | 1293/4920 |
| 近一年 | 2.04% | 2368/4361 |
| 近两年 | 27.61% | 2428/2954 |
| 近三年 | 27.03% | 1195/2253 |
| 成立以来 | 140.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.86% 1155/4961 |
-10.83% 4180/5312 |
- - |
- - |
| 2025 | 4.74% 3034/4813 |
-0.87% 2437/3635 |
6.61% 439/4076 |
-3.92% 4013/4524 |
3.14% 737/4813 |
| 2024 | 22.64% 376/3463 |
10.82% 38/2808 |
4.19% 227/3014 |
6.56% 2841/3129 |
-0.33% 1384/3463 |
| 2023 | 11.91% 63/2656 |
8.70% 449/2280 |
2.51% 135/2385 |
4.49% 150/2515 |
-3.89% 815/2655 |
| 2022 | 2.72% 25/2207 |
5.56% 31/1919 |
1.11% 1500/2016 |
-1.64% 26/2113 |
-2.16% 1782/2208 |
| 2021 | 19.56% 190/1822 |
6.87% 88/1255 |
5.54% 803/1330 |
10.38% 123/1466 |
-3.97% 1465/1822 |
| 2020 | 9.46% 843/1250 |
-11.85% 856/1028 |
6.90% 853/1067 |
12.34% 393/1164 |
3.40% 917/1184 |
| 2019 | 21.57% 647/1092 |
16.68% 665/754 |
-3.27% 382/804 |
-0.80% 618/850 |
8.59% 302/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华泰柏瑞中证红利低波ETF VS. 长安沪深300非周期A(740101) |